JNCCN 360 - Immunotherapy

Advertisement

Advertisement

Bernard J. Escudier, MD, on RCC: How the IMmotion151 Results Could Improve Treatment

Theresa M. Medina, MD, on Basal Cell Carcinoma and Immunotherapy

David J. Kwiatkowski, MD, PhD, on Clinical Implications of Neoadjuvant Atezolizumab for Resectable Non–Small Cell Lung Cancer

Recent

CML AND COVID-19: Case Report of Successful Treatment With Tocilizumab

WCLC 2020: Adding Sintilimab to Chemotherapy for Nonsquamous NSCLC

DREAMM-4 Trial Update of Belantamab Mafodotin in Myeloma

KEYNOTE-629: Pembrolizumab in Metastatic Cutaneous Squamous Cell Carcinoma

Published

Medical Literature

Subcutaneous Versus Intravenous Pertuzumab/Trastuzumab in Early Breast Cancer: Patient Perspective

Novel Chimeric Monoclonal Antibody Under Study in Metastatic Colorectal Cancer

Novel Antibody-Drug Conjugate Under Study in Platinum-Sensitive Ovarian Cancer

Phase III Trial of Triplet Regimen for HER2-Positive Metastatic Breast Cancer

Ongoing

Modest Responses With Immunotherapy Combo for Advanced Ovarian Cancer

Emerging Considerations in Triple-Negative Breast Cancer: Focus on Immunotherapy

BCOP Test-Advances in Targeted Therapy and Immunotherapy For The Treatment of Kidney Cancer

NCCN Pharmacy Updates: Advances in Targeted Therapy and Immunotherapy for the Treatment of Kidney Cancer

Available

Clinical Trials

ClinicalTrials.gov Immunotherapy

Center for Immunotherapy Clinical Research Trials

Cancer Research Institute Immunotherapy Clinical Trials

Immunotherapy Clinical Trials at Fred Hutch Cancer Research Center

NCCN Resources

Copyright © 2020 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.